BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22361935)

  • 1. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.
    Salavati A; Prasad V; Schneider CP; Herbst R; Baum RP
    Ann Nucl Med; 2012 May; 26(4):365-9. PubMed ID: 22361935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma.
    Epstude M; Tornquist K; Riklin C; di Lenardo F; Winterhalder R; Hug U; Strobel K
    Clin Nucl Med; 2013 Apr; 38(4):283-4. PubMed ID: 23429397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of Merkel cell carcinoma: a single-institution retrospective study.
    Ibrahim SF; Ahronowitz I; McCalmont TH; Hernandez Pampaloni M; Ryan JL; Yu SS
    Dermatol Surg; 2013 Sep; 39(9):1323-33. PubMed ID: 23777452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma.
    Sollini M; Taralli S; Milella M; Erba PA; Rubagotti S; Fraternali A; Roncali M; Moscarella E; Perotti G; Rufini V; Versari A
    J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1507-11. PubMed ID: 26446694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
    Basu S; Ranade R
    J Nucl Med Technol; 2016 Jun; 44(2):85-7. PubMed ID: 26471333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience.
    Siva S; Byrne K; Seel M; Bressel M; Jacobs D; Callahan J; Laing J; Macmanus MP; Hicks RJ
    J Nucl Med; 2013 Aug; 54(8):1223-9. PubMed ID: 23753187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
    George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
    Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma.
    Lu Y; Fleming SE; Fields RC; Coit DG; Carrasquillo JA
    Clin Nucl Med; 2012 Aug; 37(8):759-62. PubMed ID: 22785503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.
    Concannon R; Larcos GS; Veness M
    J Am Acad Dermatol; 2010 Jan; 62(1):76-84. PubMed ID: 20082888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma.
    Schneider C; Schlaak M; Bludau M; Markiefka B; Schmidt MC
    Clin Nucl Med; 2012 Nov; 37(11):1108-11. PubMed ID: 22996252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging.
    Buder K; Lapa C; Kreissl MC; Schirbel A; Herrmann K; Schnack A; Bröcker EB; Goebeler M; Buck AK; Becker JC
    BMC Cancer; 2014 Apr; 14():268. PubMed ID: 24742330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.
    Soydal Ç; Peker A; Özkan E; Küçük ÖN; Kir MK
    Turk J Med Sci; 2016 Feb; 46(2):409-13. PubMed ID: 27511504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
    Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
    Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Merkel Cell Carcinoma: Current Issues Regarding Diagnosis, Management, and Emerging Treatment Strategies.
    Brummer GC; Bowen AR; Bowen GM
    Am J Clin Dermatol; 2016 Feb; 17(1):49-62. PubMed ID: 26596990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.
    Baum RP; Kulkarni HR; Carreras C
    Semin Nucl Med; 2012 May; 42(3):190-207. PubMed ID: 22475428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
    Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.